10 Best Biotech Stocks to Invest In According to Billionaire Steve Cohen
On April 30, Bloomberg reported that Steve Cohen resigned as president of Point72 Asset Management, and Harry Schwefel was appointed co-CIO.
Relay Therapeutics Inc. (RLAY)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Rhenman & Partners Asset Management Henrik Rhenman | 360,000 | $3,582,000 | -22% | 0.44% |
| 2. | Hudson Bay Capital Management Sander Gerber | 311,330 | $3,097,734 | -32% | 0.01% |
| 3. | Himension Capital Jay Chen | 94,169 | $936,982 | -11% | 0.07% |
| 4. | Persistent Asset Partners Xin Huang | 16,358 | $162,762 | 0.06% | |
| 5. | Algert Coldiron Investors Peter Algert And Kevin Coldiron | 48,510 | $483 | -67% | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $20.00 | 25,000 | $500,000.00 | 403,082 | 2020-07-20 | Filing | |
| $20.00 | 25,000 | $500,000.00 | 1,021,952 | 2020-07-20 | Filing | |
| $20.00 | 25,000 | $500,000.00 | 25,000 | 2020-07-20 | Filing | |
| $20.00 | 25,000 | $500,000.00 | 25,000 | 2020-07-20 | Filing | |
| $20.00 | 10,000 | $200,000.00 | 10,000 | 2020-07-20 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $14.79 | 972 | $14,375.88 | 212,895 | 2026-04-28 | Filing | |
| $14.79 | 753 | $11,136.87 | 275,857 | 2026-04-28 | Filing | |
| $14.79 | 1,490 | $22,037.10 | 418,557 | 2026-04-28 | Filing | |
| $15.00 | 1,800 | $27,000.00 | 213,867 | 2026-04-09 | Filing | |
| $13.01 | 17,717 | $230,498.17 | 213,867 | 2026-04-07 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 12,975,299 | $129,104,225 | 0% | |
| 2. | 7,387,465 | $73,505,277 | 0% | |
| 3. | 2,940,536 | $29,248,486 | 0.01% | |
| 4. | 1,863,565 | $18,542,472 | 0% | |
| 5. | 1,564,173 | $15,563,521 | 0.39% |
News See All
10 Stocks Reeling From Huge Losses
Zimmer Biomet fell to a new 13-year low on Tuesday, slashing 10.53 percent to close at $82.84 apiece despite posting a strong earnings performance in the first quarter, as investors were rattled by the...
JonesResearch Initiates Coverage of Relay Therapeutics (RLAY) With a Hold Rating
Relay Therapeutics, Inc. (NASDAQ:RLAY) is one of the best low priced biotech stocks to invest in. On April 13, JonesResearch initiated coverage of Relay Therapeutics, Inc.
8 Best Low Priced Biotech Stocks to Invest In
On April 16, Fundstrat’s Tom Lee appeared on CNBC's 'Closing Bell' to talk about what to expect from equity markets going forward.
10 Stocks With Easy 8-20% Gains
Ten stocks finished the last trading day of the week, clocking significant gains, defying a lackluster market performance, as investors took heart from a flurry of positive developments in the industry...
Oppenheimer Notes Relay Therapeutics (RLAY) Pipeline Strength in Mutant-Selective Inhibitors
TheFly reported on January 26 that Oppenheimer upgraded RLAY from Perform to Outperform and set a $14 price target.
20 Best Biotech Stocks Under $20 to Buy Now
The U.S. biotechnology market enters 2026 as the largest global biotech market, with an estimated size of $552.39 billion in 2023, and is projected to grow to $1.24 trillion by 2030.
Relay Therapeutics, Inc. (RLAY) Shows Breakthrough Breast Cancer Results With RLY-2608
Relay Therapeutics, Inc.
Top 10 AI-Powered Biotech Stocks to Buy Now
The head biotech analyst at Goldman Sachs, Salveen Richter, made an appearance on CNBC's "Squawk Box" on July 25 to discuss a variety of topics, including the status of the biotech industry and what to...
Top 10 Stocks Under $10 That Could Triple
The Bureau of Labor Statistics reported that only 22,000 jobs were added in August, much less than the 75,000 jobs that economists polled by Dow Jones had expected.
Hedge Fund Resource Center